Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eddingpharm to Distribute Two Lilly Antibiotics in China

publication date: Nov 9, 2016
Eddingpharm signed a deal with Lilly China to promote and distribute two well-established Lilly antibiotics in China. Ceclor®, marketed in China since 1993, is an oral antibiotic that is used globally. Vancocin®, which entered China in 1996, treats MRSA (methicillin-resistant Staphylococcus aureus). Lilly said it hopes the relationship with Eddingpharm raises the revenues from the vaccines. The company plans to introduce ten new drugs in China over the next decade and wants to focus its resources on other novel products, both established and new-to-China. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital